Opioid use among female breast cancer patients using different adjuvant endocrine therapy regimens
To explore differences in opioid use across different adjuvant endocrine therapy (AET) regimens, factors associated with opioid use, and the impact of opioid use on overall survival in female breast cancer patients treated with AET.
This retrospective study analyzed 2006–2012 SEER-Medicare datasets, following patients for at least two years from the index date, defined as the first date they filled an AET prescription. The study included adult women with incident, primary, hormone-receptor-positive, stage I–III breast cancer. They were also first-time AET users, and fee-for-service Medicare enrollees continuously enrolled in Medicare Parts A, B, and D. The main independent variable was the AET regimen. We measured whether patients used opioids after the initiation of AET.
After the adjustment of inverse probability treatment weights and unbalanced covariates, the average treatment effect probabilities of opioid use were similar between those who used aromatase inhibitors (AI) only and those used tamoxifen (TAM) only (56.2 vs. 55.3%, respectively). Opioid use probabilities for those who switched from AI to TAM were higher than those for the TAM-only and AI-only groups. Opioid use was also significantly associated with AET non-adherence. Opioid users had a significantly higher risk of death (adjusted hazard ratio [HR] = 1.59, p < 0.001).
Switching from AI to TAM was associated with a high likelihood of opioid use. Opioid use was significantly associated with AET non-adherence and higher risk of mortality in female Medicare beneficiaries with breast cancer even after adjusting for adherence.
KeywordsOpioid Adjuvant endocrine therapy Breast cancer Medicare Tamoxifen Aromatase inhibitor
Compliance with ethical standards
Conflict of interest
The authors declared no conflicts of interest.
- 1.Johannsen M, Christensen S, Zachariae R, Jensen AB (2015) Socio-demographic, treatment-related, and health behavioral predictors of persistent pain 15 months and 7–9 years after surgery: a nationwide prospective study of women treated for primary breast cancer. Breast Cancer Res Treat 152(3):645–658. doi: 10.1007/s10549-015-3497-x CrossRefPubMedGoogle Scholar
- 3.International Association for the Study of Pain (2009). Epidemiology of Cancer Pain. http://www.iasp-pain.org/files/Content/ContentFolders/GlobalYearAgainstPain2/CancerPainFactSheets/Epidemiology_Final.pdf. Accessed 27 Apr 2017
- 9.Lintermans A, Van Asten K, Wildiers H et al (2014) A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI. Breast Cancer Res Treat 146(1):109–116. doi: 10.1007/s10549-014-2986-7 CrossRefPubMedGoogle Scholar
- 16.SAS Institute, Inc (2011) SAS/STAT user’s guide, v. 9.3. https://support.sas.com/documentation/cdl/en/statug/63962/PDF/default/statug.pdf. Accessed 27 Apr 2017
- 18.McCaffrey D, Burgette L, Griffin BA, Craig Martin (2016) Propensity scores for multiple treatments: a tutorial for the MNPS macro in the twang SAS macros. Rand Corporation. https://www.rand.org/pubs/tools/TL169z1.readonline.html. Accessed 27 Apr 2017